
Conference Coverage
Latest Content

ICYMI: Highlights From ASCO 2025

Long-Term ALPINE Data Demonstrate Zanubrutinib’s Efficacy in R/R CLL/SLL

Trabectedin Plus Olaparib Improves PFS in Some Patients With STS

FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy

Top 5 Most-Read Pulmonary Fibrosis Content of 2025

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Advances in radiopharmaceuticals, precision medicine, and the importance of diversity in clinical trials for multiple myeloma and cancer care were among the most popular articles with readers in 2025.

Studies indicate that ultrasound-based AI models significantly outperform sonographers in diagnosing ovarian cancer.

A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) glycemic measure.

This study found that certain characteristics in linked electronic health record data across episodes of care can help identify patients with Alzheimer disease and related dementias at high risk of 30-day readmissions.

Fuzuloparib extended progression-free survival, regardless of the addition of apatinib in patients with newly diagnosed advanced ovarian cancer.

This year's top inflammation article highlighted the first FDA-approved treatment for patients with bronchiectasis.

Our top RSV content of 2025 included how nirsevimab and clesrovimab changed RSV prevention among younger patients, as well as the positive impact of RSV vaccination in older individuals.

Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on disease burden and dysphagia indicators.

The conference focused on how to improve eye care across the country, including new methods of treating dry eye and utilizing new technologies to catch myopia earlier.

Patients with DLBCL who were treated with R-CHOP and quickly relapsed or were refractory to therapy had poor outcomes on second-line therapy.





















































